Treatment Options for Platinum Resistant Ovarian Cancer-Recording - Treatment Options for Platinum Resistant Ovarian Cancer

Video Transcription

Video Summary

The video is a webinar titled "Treatment Options for Platinum-Resistant Ovarian Cancer" moderated by Dr. Kathleen Moore, who is a gynecological oncologist and the Associate Director of Clinical Research at the Stevenson Cancer Center. The webinar is supported by Immunogen and focuses on the treatment of platinum-resistant ovarian cancer, specifically discussing a recently FDA-approved medication called mirvotuximab soravtansine. The speaker, Dr. Ursula Matulonis, who is the Chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute, explains that mirvotuximab is an antibiotic drug conjugate that targets the folate receptor alpha (FR-alpha) in ovarian cancer cells. The drug has shown clinically meaningful anti-tumor activity and a 32.4% overall response rate. It is well-tolerated, with low-grade reversible ocular and gastrointestinal side effects being the most common. However, it has a black box warning for ocular toxicities, and patients are advised to receive prophylactic eye care before starting treatment. The presentation also mentions ongoing trials and future opportunities for targeted therapy in ovarian cancer using antibody drug conjugates. The webinar concludes with a Q&A session, addressing questions about the companion diagnostic test, patient eligibility, and mitigation strategies for ocular toxicities. Overall, the webinar provides an update on treatment options for platinum-resistant ovarian cancer and highlights the potential of mirvotuximab soravtansine as a new therapeutic option.

Keywords

Treatment Options

Platinum-Resistant Ovarian Cancer

Webinar

Mirvotuximab Soravtansine

Folate Receptor Alpha

Ocular Toxicities

Antibody Drug Conjugates